Marcus-André Deutsch

Marcus-André Deutsch

Auto-generated profile, based on publicly available information

Marcus-André Deutsch

Deutsches Herzzentrum München and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
OBOle De Backer
Ole De Backer
TPThomas Pilgrim
Thomas Pilgrim
MSMatheus Simonato
Matheus Simonato
GMG. Burkhard Mackensen
G. Burkhard Mackensen
CFClaudia Fiorina
Claudia Fiorina
DDDanny Dvir
Danny Dvir

1 January 2013 in Disease Markers
Verified
Journal Article
Open access
PDF file
MKMatthias Kornek
Matthias Kornek
MDMarcus-André Deutsch
Marcus-André Deutsch
SEStefan Eichhorn
Stefan Eichhorn
HLHarald Lahm
Harald Lahm
SWStefan Wagenpfeil
Stefan Wagenpfeil
JBJohannes Boehm
Johannes Boehm
Background. Cardiac surgery-associated acute kidney injury (CSA-AKI) depicts a major complication after cardiac surgery using cardiopulmonary bypass (CPB).Objective. CSA-AKI has clearly been linked to increased perioperative morbidity and mortality. Dysregulations of vasomotor tone are assumed to be causal for CSA-AKI. While catechol-O-methyltransferase (COMT) is involved in metabolizing catecholamines, a single-nucleotide polymorphism (SNP) in the COMT gene leads to different enzyme activities according to genotype. Pilot studies found associations between those COMT genotypes and CSA-AKI.Methods. We prospectively included 1741 patients undergoing elective cardiac surgery using cardiopulmonary bypass (CPB). Patients were genotyped for COMT-Val158Met-(G/A) polymorphism (rs4680).Results. Demographic characteristics and procedural data revealed no significant differences between genotypes. No association between COMT genotypes and the RIFLE criteria could be detected. A multiple linear regression analysis for postoperative creatinine increase revealed highly significant associations for aortic cross-clamp time (P<0.001), CPB time (P<0.001), norepinephrine (P<0.001), and age (P<0.001). No associations were found for COMT genotypes or baseline creatinine. With anR2=0.39and a sample size of 1741, the observed power of the regression analysis was >99%.Conclusions. Based on our results, we can rule out an association between the COMT-Val158Met-(G/A) polymorphism and the appearance of CSA-AKI.

14 March 2018 in Stem Cells International
Verified
Journal Article
Open access
PDF file
EDElda Dzilic
Elda Dzilic
HLHarald Lahm
Harald Lahm
MDMartina Dreßen
Martina Dreßen
MDMarcus-André Deutsch
Marcus-André Deutsch
RLRüdiger Lange
Rüdiger Lange
SDStefanie Doppler
Stefanie Doppler
Genome editing is a powerful tool to study the function of specific genes and proteins important for development or disease. Recent technologies, especially CRISPR/Cas9 which is characterized by convenient handling and high precision, revolutionized the field of genome editing. Such tools have enormous potential for basic science as well as for regenerative medicine. Nevertheless, there are still several hurdles that have to be overcome, but patient-tailored therapies, termed precision medicine, seem to be within reach. In this review, we focus on the achievements and limitations of genome editing in the cardiovascular field. We explore different areas of cardiac research and highlight the most important developments: (1) the potential of genome editing in human pluripotent stem cells in basic research for disease modelling, drug screening, or reprogramming approaches and (2) the potential and remaining challenges of genome editing for regenerative therapies. Finally, we discuss social and ethical implications of these new technologies.

1 September 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
GWGuy Witberg
Guy Witberg
JSJasmin Shamekhi
Jasmin Shamekhi
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
AFAdolfo Ferrero-Guadagnoli
Adolfo Ferrero-Guadagnoli
LSLars Soendergaard
Lars Soendergaard
RKRan Kornowski
Ran Kornowski

15 May 2019 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
SVStephanie Voss
Stephanie Voss
MDMarcus-André Deutsch
Marcus-André Deutsch
JSJohanna Schechtl
Johanna Schechtl
MEMagdalena Erlebach
Magdalena Erlebach
KSKonstantinos Sideris
Konstantinos Sideris
SBSabine Bleiziffer
Sabine Bleiziffer
Background There is a growing use of cerebral protection devices in patients undergoing transcatheter aortic valve replacement (TAVR). We aimed to analyze if the use of these devices itself has an impact on the complexity and the risk of TAVR. Methods Between February 2016 and July 2017, 391 patients underwent transfemoral TAVR with Medtronic CoreValve Evolut R (n = 196) or Edwards Sapien 3 (n = 195). In 39 patients, the Claret Sentinel™ embolic protection device (CS-EPD) was used. Prospectively collected data were retrospectively analyzed, comparing fluoroscopy/operation time, amount of contrast used, vascular events, and postprocedural renal function in TAVR patients with (n = 39) and without (n = 352) CS-EPD. Results The CS-EPD was placed through the right radial (n = 35) or brachial (n = 4) artery. Procedural success rate defined as correct deployment and retraction of both filters was 94.9%. No device-related vascular complications occurred. TAVR patients with CS-EPD showed a significantly higher total operation time, total fluoroscopy time, and amount of used contrast (85.4 ± 39.3 vs. 64 ± 29.8 minutes, p = 0.002; 20.7 ± 9.3 vs. 13.7 ± 7 minutes, p ≤ 0.001; 133.7 ± 42.6 vs. 109.7 ± 44.5 mL, p = 0.001). Comparing the initial third of patients receiving a CS-EPD with the last third of CS-EPD cases, procedural time had decreased significantly (102.5 ± 34.9 vs. 67 ± 11.9; p = 0.002). There were no differences in postprocedural renal failure (p = 0.80). Conclusion Our data add evidence that the application of the CS-EPD is not associated with an additional risk for the patient. Although procedural time and amount of contrast are still higher when using the CS-EPD, there were no device-related complications or increased incidence of renal failure.